Chemical Compound

irbesartan

CAS Registry Number 138402-11-6

Back to search Request a Quote

Primary Record

irbesartan

In stock: 6,703 g
Purity: 99.6 %
CAS: 138402-11-6

Compound Identifiers & Properties

CAS: 138402-11-6
PubChem CID: 3749
SMILES: CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
Canonical SMILES: CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1

Names & Synonyms

irbesartan
Avapro
Aprovel
Karvea
138402-11-6
Irbesartan BMS
Sarbevel
Irbetan
Irbesartan-d3
Irbesartan teva
Irbesartan Krka
ifirmasta
Irbesartan Zentiva
Irbesarran
Lrbesartan
Sabervel
Avalide
irbesartanum
Irbesartan Winthrop
Irbesartan D4
[3H]irbesartan
Irbesartan?
Irbesartan HCl
Aprovel;
Irbesartan CRS
Irbesartan-d7
Avapro;
BMS-186295
Irbesartan free base
Avapro (TN)
Irbesartan [USAN:INN]
SR-47436
Aprovel (TN)
Avalide (TN)
Karvea (TN)
Irbesartan (Avapro)
Irbesartan(Avapro)/
Irbesartan (Standard)
Irbesartan hydrochloride
IRBESARTAN 1G
IRBESARTAN 5G
Spectrum_001751
2,4-Dichloropyrimidine
Ac-Lys(Z)-OH
SR 47436
IRBESARTAN [MI]
RefChem:57688
BMS 186295
DTXSID0023169
BMS Brand of Irbesartan
MFCD00864464
AC1L1GMK
C25H28N6O
IRBESARTAN [INN]
IRBESARTAN [JAN]
Spectrum2_001675
Spectrum3_000994
Spectrum4_001122
Spectrum5_001288
CHEMBL1513
IRBESARTAN [USAN]
YOSHYTLCDANDAN-UHFFFAOYSA-N
IRBESARTAN [VANDF]
D00JAU
D0F8KG
UNII-J0E2756Z7N
IRBESARTAN [MART.]
SCHEMBL4246
CHEBI:5959
DTXCID903169
IRBESARTAN [USP-RS]
IRBESARTAN [WHO-DD]
J0E2756Z7N
BSPBio_002687
GTPL589
KBioGR_001603
KBioSS_002231
HSDB 8215
MLS000759408
MLS001424099
BIDD:GT0347
Irbesartan (JAN/USAN/INN)
IRBESARTAN [EMA EPAR]
NSC-758696
SCHEMBL285754
SPECTRUM1504259
SPBio_001889
GTPL6908
Irbesartan (JP18/USP/INN)
Irbesartan - Bio-X trade mark
Irbesartan [USAN:USP:INN:BAN]
orb1308006
Jsp002315
IRBESARTAN [EP IMPURITY]
IRBESARTAN [ORANGE BOOK]
ERK5-3D06
HY-B0202R
KBio2_002231
KBio2_004799
KBio2_007367
KBio3_001907
KS-00000ISW
138402-11-6 (free base)
C09CA04
CID3749
COAPROVEL COMPONENT IRBESARTAN
EBD8758
IRBESARTAN [EP MONOGRAPH]
IRBESARTAN [USP IMPURITY]
Bristol Myers Brand of Irbesartan
BCPP000202
GLXC-04552
HMS1922J05
HMS2051L08
HMS2093E16
HMS2232F23
HMS3370B06
HMS3393L08
HMS3715L04
HMS5087C17
IRBESARTAN [USP MONOGRAPH]
Pharmakon1600-01504259
SanofiWinthrop Brand of Irbesartan
AVALIDE COMPONENT IRBESARTAN
IFIRMACOMBI COMPONENT IRBESARTAN
BCP02004
CID:3749
HY-B0202
MSK10063
SR47436
ZINC3872931
Tox21_111433
ABP000523
AC-537
BDBM50042235
C25-H28-N6-O
CCG-39091
MFCD18384966
NCGC00095122-01
NP3710
NSC758696
STK645362
AKOS005576396
AKOS015895353
Irbesartan, >=98% (HPLC), powder
Tox21_111433_1
AB07472
AM90289
BCP9000792
CCG-101012
CS-2140
DB01029
EBC-145051
FI24648
KS-1151
NC00262
NSC 758696
3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
NCGC00095122-02
NCGC00095122-03
NCGC00095122-04
NCGC00095122-05
NCGC00095122-14
4CA-0654
AK-57149
AN-15743
BC207567
BI164582
BR-57149
CPD000466306
H931
LS-60064
SAM001246548
SC-08814
SMR000466306
SY051244
SBI-0206769.P001
SID:376229507
AB0013366
AB1009632
J549.417F
TL8000875
2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
A-779
A5970
CAS-138402-11-6
FT-0601598
FT-0670413
I0859
NS00000387
S1507
SR-47436;BMS-186295
ST24028252
BMS-186295, SR-47436
A10477
C07469
D00523
J10394
S-1797
1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
54246-EP2270011A1
54246-EP2295406A1
54246-EP2295422A2
54246-EP2298772A1
54246-EP2298776A1
54246-EP2298779A1
54246-EP2301923A1
54246-EP2301931A1
54246-EP2305219A1
54246-EP2308562A2
54246-EP2308839A1
AB00639954-06
AB00639954_07
AB00639954_08
2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro(4.4)non-1-en-4-one
2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
402I116
A807387
C081309
EN300-37158602
L000319
Q947266
SR-05000001997
1,3-Diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-
I06-0690
IBERSARTAN/HYDROCHLOROTHIAZIDE COMPONENT IBERSARTAN
SR-05000001997-1
(-)-Styrene glycol; (R)-(-)-Phenylethylene glycol
2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-one
8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one
BRD-K60038276-001-02-5
BRD-K60038276-001-03-3
BRD-K60038276-001-08-2
BRD-K60038276-001-09-0
IBERSARTAN/HYDROCHLOROTHIAZIDE TEVA COMPONENT IBERSARTAN
1185120-76-6
BMS-186295, SR-47436,Aprovel, Karvea, Irbesartan
D000077405
IBERSARTAN/HYDROCHLOROTHIAZIDE ZENTIVA COMPONENT IBERSARTAN
2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one
Irbesartan, European Pharmacopoeia (EP) Reference Standard
2-BUTYL-3-[[2'-(2H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1,3-DIAZASPIRO[4.4]NON-1-EN-4-ONE
2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
3-BUTYL-2-[[4-[2-(2H-TETRAZOL-5-YL)PHENYL]PHENYL]METHYL]-2,4-DIAZASPIRO[4.4]NON-3-EN-1-ONE
Irbesartan, United States Pharmacopeia (USP) Reference Standard
2-Butyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[4.4]non-1-en-4-one
3-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
Irbesartan, Pharmaceutical Secondary Standard; Certified Reference Material
2-butyl-3-[ p -( o -1 H -tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one
2-butyl-3-[ p-(o-1 H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one
1,3-Diazaspiro[4.4]non-1-en-4-one,2-butyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
1-[[2 -(2H-Tetrazole-5-yl)-1,1 -biphenyl-4-yl]methyl]-2-butylspiro[2-imidazoline-4,1 -cyclopentane]-5-one
1-[4-[2-(1H-Tetrazole-5-yl)phenyl]benzyl]-2-butylspiro[1H-imidazole-4(5H),1 -cyclopentane]-5-one
1216883-23-6
1242281-36-2
1329496-43-6
2-(~2~H_9_)Butyl-3-{[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-(n-butyl)-3-[[2'-(tetrazol-5-yl)biphenyl-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4.4)non-1-en-4-one
2-butyl-3-((4-(2-(2H-1,2,3,4-tetrazol-5-yl)phenyl)phenyl)methyl)-1,3-diazaspiro(4.4)non-1-en-4-one
2-butyl-3-((4-(2-(2H-tetrazol-5-yl)phenyl)phenyl)methyl)-1,3-diazaspiro(4.4)non-1-en-4-one
2-butyl-3-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one
2-Butyl-3-[[2 -(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
2-BUTYL-3-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1,3-DIAZASPIRO[4.4]NON-1-EN-4-ONE
2-Butyl-3-[2 -(1H-tetrazole-5-yl)-4-biphenylylmethyl]-1,3-diazaspiro[4.4]nona-1-ene-4-one
2-Butyl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1,3-diaza-spiro[4.4]non-1-en-4-one
2-butyl-3-{[2''-(1H-tetrazol-5-yl)[1,1''-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-{[2''-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-{[2'-(2H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-n-butyl-3-<<2'-(1H-tetrazol-5-yl)biphenyl-4-yl>methyl>-1,3-diazaspiro<4.4>non-1-en-4-one;
3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)-methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
3-((2'-(1H-Tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one =98.0% (by HPLC, titration analysis)
3-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
3-((2`-(1H-Tetrazol-5-yl)-[1,1`-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
3-[[2 inverted exclamation mark -(1H-Tetrazol-5-yl)-[1,1 inverted exclamation mark -biphenyl]-4-yl]methyl]-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
604-078-2
Irbesartan, 99%, a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist - 1G 1g
Irbesartan; 2-Butyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one